538 related articles for article (PubMed ID: 20406307)
1. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
[TBL] [Abstract][Full Text] [Related]
2. Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
Gai W; Zou W; Lei L; Luo J; Tu H; Zhang Y; Wang K; Tien P; Yan H
Viral Immunol; 2008 Mar; 21(1):27-37. PubMed ID: 18355120
[TBL] [Abstract][Full Text] [Related]
3. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
5. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
[TBL] [Abstract][Full Text] [Related]
6. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice.
Lu X; Chen Y; Bai B; Hu H; Tao L; Yang J; Chen J; Chen Z; Hu Z; Wang H
Immunology; 2007 Dec; 122(4):496-502. PubMed ID: 17680799
[TBL] [Abstract][Full Text] [Related]
7. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
[TBL] [Abstract][Full Text] [Related]
8. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
[TBL] [Abstract][Full Text] [Related]
9. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.
Shim BS; Stadler K; Nguyen HH; Yun CH; Kim DW; Chang J; Czerkinsky C; Song MK
Virol J; 2012 Sep; 9():215. PubMed ID: 22995185
[TBL] [Abstract][Full Text] [Related]
10. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.
Yao Q; Vuong V; Li M; Compans RW
Vaccine; 2002 Jun; 20(19-20):2537-45. PubMed ID: 12057610
[TBL] [Abstract][Full Text] [Related]
12. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
[TBL] [Abstract][Full Text] [Related]
13. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
[TBL] [Abstract][Full Text] [Related]
14. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
[TBL] [Abstract][Full Text] [Related]
15. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
16. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs.
Ishii K; Hasegawa H; Nagata N; Mizutani T; Morikawa S; Suzuki T; Taguchi F; Tashiro M; Takemori T; Miyamura T; Tsunetsugu-Yokota Y
Virology; 2006 Aug; 351(2):368-80. PubMed ID: 16678878
[TBL] [Abstract][Full Text] [Related]
17. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
Siadat-Pajouh M; Cai L
Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.
Guerrero RA; Ball JM; Krater SS; Pacheco SE; Clements JD; Estes MK
J Virol; 2001 Oct; 75(20):9713-22. PubMed ID: 11559804
[TBL] [Abstract][Full Text] [Related]
19. Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.
Luo F; Feng Y; Liu M; Li P; Pan Q; Jeza VT; Xia B; Wu J; Zhang XL
Clin Vaccine Immunol; 2007 Aug; 14(8):990-7. PubMed ID: 17596427
[TBL] [Abstract][Full Text] [Related]
20. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Schulze K; Staib C; Schätzl HM; Ebensen T; Erfle V; Guzman CA
Vaccine; 2008 Dec; 26(51):6678-84. PubMed ID: 18805454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
